Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PI3Kγ AKAP interface refers to the protein-protein interaction between the catalytic subunit of phosphoinositide 3-kinase gamma (p110γ) and the regulatory subunits (specifically RIIα) of protein kinase A (PKA) [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153153/]. In this context, PI3Kγ functions as a non-canonical A-kinase anchoring protein (AKAP) that scaffolds PKA and phosphodiesterases (PDE3B and PDE4) into a signaling microdomain to regulate local cAMP levels [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754836/]. In diseases like heart failure and chronic obstructive pulmonary disease, this complex is often dysregulated, leading to impaired cAMP signaling and receptor downregulation [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153153/]. Therapeutic strategies focus on using disruptor peptides, such as DRI-Pep #20 or PI3Kγ mimetic peptides, to uncouple PKA from PI3Kγ, thereby restoring local cAMP concentrations and improving physiological functions like cardiac contractility and airway relaxation [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10927144/]. This target is particularly attractive because it allows for compartment-specific signaling modulation without affecting the global kinase activity of PI3Kγ or other PKA-AKAP complexes [ResearchGate, https://www.researchgate.net/publication/384784444_Unlocking_cAMP_modulation_a_new_peptide_targeting_PI3Kg_in_pulmonary_cells]. By targeting the scaffold function rather than the enzymatic activity, these drugs aim to achieve higher specificity and fewer side effects compared to traditional kinase inhibitors.
Disruption of the protein-protein interaction between PI3Kγ and PKA regulatory subunits to restore local cAMP signaling microdomains and prevent β-adrenergic receptor downregulation [NIH, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153153/].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphoinositide 3-kinase gamma-A-kinase anchoring protein interface (PI3Kγ-AKAP interface).